




Information *for Families and* Caregivers



General Information

The **CALMA** Clinical Trial is a **Phase 2**, FDA-registered research study for people living with **Alzheimer's disease** who experience agitation.

Agitation can include **restlessness, pacing, repeated questions, irritability, verbal outbursts, or aggression**. These symptoms are very challenging for both patients and caregivers.


The purpose of **CALMA** is to study an investigational medicine, **IGC-AD1**, an oral liquid solution that contains tetrahydrocannabinol (THC) and melatonin. In earlier research, this medicine was shown to be safe and well-tolerated. Now, we are testing whether it can help **reduce agitation symptoms** and continue researching safety and tolerability.




Eligibility Criteria →

A *person may qualify* if they:

- Have a diagnosis of probable **Alzheimer's disease**
- Have a **caregiver** who knows them well, can attend study visits, and help with at-home monitoring
- Experience agitation symptoms such as **restlessness, pacing, aggression, verbal outbursts, or repeated behaviors**



Agitation Behaviors





The study doctor will make the final decision about eligibility after medical screening.

Benefits →



If you decide to participate, you will receive at **no cost**:

- All study-related medications
- Comprehensive **study-related** care and regular check-ins
- Access to **specialized doctors** and researchers in Alzheimer's disease
- An easy-to-use digital blood pressure monitor and weighing scale for at-home monitoring
- **Compensation for time and effort** for both the participant and caregiver
- Coverage of travel expenses, parking, and transportation for visits

Health insurance is not required to take part in the CALMA study.

→ The study lasts about **8 weeks** (50–57 days)

→ There are 4 to 6 in-person clinic visits plus phone check-ins




→ The participant will take either **IGC-AD1** or a placebo (an inactive solution that looks the same)

→ Participation can be stopped at **any time**

What to Expect





Rights and Support

-  Participation is **voluntary**
-  You may **ask questions** at **any time** before or during the study
-  Caregivers are recognized as partners in this process and **receive** ongoing **support** from the study team

Fill out this
form and we
will reach out
or Contact Us:



Contact *us*:

-  calma@igcpharma.com
-  <https://igcpharma.com/calma>



CALMA

CLINICAL TRIAL: ALZ-AGITATION